Research programme: small molecule therapeutics - Kareus Therapeutics

Drug Profile

Research programme: small molecule therapeutics - Kareus Therapeutics

Latest Information Update: 14 Feb 2014

Price : $50

At a glance

  • Originator Kareus Therapeutics
  • Class Small molecules
  • Mechanism of Action Cannabinoid receptor modulators; Enkephalin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Cancer; Multiple sclerosis
  • Research Inflammatory pain; Neuropathic pain

Most Recent Events

  • 14 Feb 2014 Research programme: small molecule therapeutics - Kareus Therapeutics is available for licensing as of 14 Feb 2014. http://www.kareustherapeutics.com/
  • 07 Jan 2013 Preclinical development is ongoing in Switzerland
  • 13 Jun 2011 Preclinical trials in Alzheimer's disease in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top